Fred Alger Management’s TG Therapeutics TGTX Stock Holding History

Fred Alger Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$617K	Buy	+18,588	New	+$554K	﹤0.01%	372
2025 Q3	–	Sell	-88,198	Closed	-$2.76M	–	497
2025 Q2	$2.76M	Buy	+88,198	New	+$3.28M	0.01%	293
2021 Q3	–	Sell	-72,209	Closed	-$2.8M	–	559
2021 Q2	$2.8M	Sell	72,209 -3,094	-4%	-$122K	0.01%	335
2021 Q1	$3.63M	Sell	75,303 -11,749	-13%	-$564K	0.01%	313
2020 Q4	$4.53M	Buy	87,052 +20,778	+31%	+$702K	0.01%	284
2020 Q3	$1.77M	Sell	66,274 -8,726	-12%	-$201K	0.01%	312
2020 Q2	$1.46M	Buy	75,000 +34,000	+83%	+$548K	﹤0.01%	325
2020 Q1	$403K	Buy	+41,000	New	+$518K	﹤0.01%	369
2016 Q4	–	Sell	-70,000	Closed	-$542K	–	523
2016 Q3	$542K	Buy	70,000 +1,900	+3%	+$12.2K	﹤0.01%	350
2016 Q2	$413K	Hold	68,100	–	–	﹤0.01%	387
2016 Q1	$580K	Sell	68,100 -12,350	-15%	-$108K	﹤0.01%	408
2015 Q4	$960K	Hold	80,450	–	–	﹤0.01%	387
2015 Q3	$811K	Hold	80,450	–	–	﹤0.01%	398
2015 Q2	$1.33M	Buy	80,450 +7,450	+10%	+$118K	0.01%	410
2015 Q1	$1.13M	Buy	+73,000	New	+$1.11M	0.01%	489

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fred Alger Management's TGTX Position: Q1 2026 in Review

Fred Alger Management opened a new position in TG Therapeutics (TGTX) in Q1 2026: 18,588 shares worth $617K. The stake represents ﹤0.01% of the portfolio and ranks #372 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in TGTX as recently as Q2 2025.

Fred Alger Management first reported a position in TGTX in Q1 2015 and has held it in 15 quarters since. The position peaked at $4.53M in Q4 2020. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Fred Alger Management held 18,588 shares of TG Therapeutics worth $617K as of Q1 2026.
TG Therapeutics was a new Fred Alger Management position in Q1 2026.
TG Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #372 holding.
Fred Alger Management first reported a position in TG Therapeutics in Q1 2015 and has held it in 15 quarters since.
Fred Alger Management's TG Therapeutics position peaked at $4.53M in Q4 2020.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.